# Nuclide record nct05219500 (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/nct05219500/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "nct05219500", "NCT05219500" ;
  schema:name "Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST)."@en ;
  schema:alternateName "TATCIST"@en ;
  schema:description "A phase 2 trial of FPI-2265 in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting."@en ;
  schema:url <https://nuclide.cc/trials/nct05219500/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05219500> ;
  nuclide:status "active" ;
  nuclide:tag "ctgov-ingest" ;
  nuclide:phase "2" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mcrpc/> ;
  nuclide:drugs <https://nuclide.cc/drugs/fpi-2265/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> .